The use of anabolic androgenic steroids (AAS) has grown among practitioners of recreational bodybuilding, with significant contributions of designer steroids, aiming muscle hypertrophy in healthy subjects. The abusive use of AAS in general is associated with adverse effects; one of the most worrisome is cancer development. The aim of this study was to evaluate the effectiveness of the cytokinesis block micronucleus (CBMN) test in human lymphocytes in identifying risk groups for cancer development in users of AAS. Blood was collected from 15 AAS users bodybuilders (G1), 20 non-users bodybuilders (G2) and 20 non-users sedentary (G3). MN analysis was performed on a minimum of 1000 binucleated lymphocytes. The occurrence of MN was significantly higher (p < 0.05) in individuals of G1 compared to G2 and G3. The results indicate the sensitivity of CBMN in human lymphocytes in the identification of chromosomal damage in consequence of AAS.
GeorgeAJ. The actions and side effects of anabolic steroids in sport and social abuse. Andrologie2003; 13: 354–366.
6.
KokkeviAFotiouAChilevaA. Daily exercise and anabolic steroids use in adolescents: a cross-national european study. Subst Use Misuse2008; 43: 2053–2065.
7.
IriartJABChavesJCde OrleansRG. Culto ao corpo e uso de anabolizantes entre praticantes de musculação. Cad Saúde Pública2009; 25: 773–782.
8.
PopeHGKanayamaGHudsonJI. Risk factors for illicit anabolic-androgenic steroid use in male weightlifters: a cross-sectional cohort study. Biol Psychiatry2012; 71: 254–261.
9.
JohnstonLDO’MalleyPMBachmanJG. Monitoring the Future national Results on Adolescent Drug Use: Overview of Key Findings, 2011. Ann Arbor: Institute for Social Research, The University of Michigan; 2012, p. 85.
10.
DunnMWhiteV. The epidemiology of anabolic-androgenic steroid use among australian secondary school students. J Sci Med Sport2011; 14: 10–14.
11.
ScarthJPClarkeADTealeP. Comparative in vitro metabolism of the “designer” steroid estra-4,9-diene-3,17-dione between the equine, canine and human: identification of target metabolites for use in sports doping control. Steroids2010; 75: 643–652.
CavalcantiGALealFDGarridoBC. Detection of designer steroid methylstenbolone in “Nutritional Supplement” using gas chromatography and tandem mass spectrometry: elucidation of Its urinary metabolites. Steroids2013; 78: 228–233.
14.
Sinha-HikimIArtazaJWoodhouseL. Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am J Physiol Endocrinol Metab2002; 283: 154–164.
15.
ShahidiNT. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin Ther2001; 23: 1355–1390.
16.
IsmailTFAngellPJJabbourA. Cardiac effects of anabolic steroid use amongst recreational body builders - a CMR Study. J Cardiov Magn Reson2012; 14: 186.
17.
SocasLZumbadoMPérez-LuzardoO. Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. Br J Sports Med2005; 39: 1–4.
TanRSScallyMC. Anabolic steroid-induced hypogonadism--towards a unified hypothesis of anabolic steroid action. Med Hypotheses2009; 72: 723–728.
20.
KanayamaGHudsonJIPopeHGJr. Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse. Drug Alcohol Depend2008; 98: 1–12.
21.
MelloniRHRicciLA. Adolescent exposure to anabolic/androgenic steroids and the neurobiology of offensive aggression: a hypothalamic neural model based on findings in pubertal Syrian hamsters. Horm Behav2010; 58: 177–191.
22.
KosakaATakahashiHYajimaY. Hepatocellular carcinoma associated with anabolic steroid therapy: report of a case and review of the Japanese literature. J Gastroenterol1996; 31: 450–454.
HardtAStippelDOdenthalM. Development of hepatocellular carcinoma associated with anabolic androgenic steroid abuse in a young bodybuilder: a case report. Case Rep Pathol2012; 2012: 1–5.
25.
HanahanDWeinbergRA. Hallmarks of cancer: the next generation. Cell2011; 144: 646–674.
26.
BeckmanRALoebLA. Genetic instability in cancer: theory and experiment. Semin Cancer Biol2005; 15: 423–435.
27.
BonassiSEl-ZeinRBolognesiC. Micronuclei frequency in peripheral blood lymphocytes and cancer risk: evidence from human studies. Mutagenesis2011; 26: 93–100.
28.
LoncarDMilosević-DjordjevićOZivanovićA. Effect of a low-dose ethinylestradiol and gestodene in combination on the frequency of micronuclei in human peripheral blood lymphocytes of healthy women in vivo. Contraception2004; 69: 327–331.
29.
Torres-BugarínOCovarrubias-BugarínRZamora-PerezAL. Anabolic androgenic steroids induce micronuclei in buccal mucosa cells of bodybuilders. Br J Sports Med2007; 41: 592–596.
30.
MartinsRAGomesGASAguiarO. Chromosome damage and cytotoxicity in oral mucosa cells after 2 months of exposure to anabolic steroids (decadurabolin and winstrol) in weight lifting. Steroids2010; 75: 952–955.
31.
El-ZeinRASchabathMBEtzelCJ. Cytokinesis-blocked micronucleus assay as a novel biomarker for lung cancer risk. Cancer Res2006; 66: 6449–6456.
32.
BonassiSZnaorACeppiM. An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans. Carcinogenesis2007; 28: 625–631.
33.
IarmarcovaiGCeppiMBottaA. Micronuclei frequency in peripheral blood lymphocytes of cancer patients: a meta-analysis. Mutat Res2008; 659: 274–283.
34.
ChangPLiYLiD. Micronuclei levels in peripheral blood lymphocytes as a potential biomarker for pancreatic cancer risk. Carcinogenesis2011; 32: 210–215.
FenechM. The in vitro micronucleus technique. Mutat Res2000; 455: 81–95.
37.
JoostenHFvan AckerFAvan den DobbelsteenDJ. Genotoxicity of hormonal steroids. Toxicol Lett2004; 151: 113–134.
38.
KayaniMAParryJM. The detection and assessment of the aneugenic potential of selected oestrogens, progestins and androgens using the in vitro cytokinesis blocked micronucleus assay. Mutat Res2008; 651: 40–45.
39.
DornSBBoltHMThevisM. Induction of micronuclei in V79 cells by the anabolic doping steroids tetrahydrogestrinone and trenbolone. Arch Toxicol2008; 82: 257–263.
40.
Bragança-PereiraCA. Teste estatístico para comparar proporções em problemas de citogenética. In: Rabello-GayMNRodriguesMALRMontelleone-NetoR (eds) Mutagênese, carcinogênese e teratogênese: métodos e critérios de avaliação. São Paulo: Sociedade Brasileira de Genética, 1991, pp. 113–121.
41.
Van EenooPDelbekeFT. Metabolism and excretion of anabolic steroids in doping control--new steroids and new insights. J Steroid Biochem2006; 101: 161–178.
42.
BonassiSNeriMPuntoniR. Validation of biomarkers as early predictors of disease. Mutat Res2001; 480–481: 349–358.
43.
BonassiSAuWW. Biomarkers in molecular epidemiology studies for health risk prediction. Mutat Res2002; 511: 73–86.
44.
FenechM. Biomarkers of genetic damage for cancer epidemiology. Toxicology2002; 181–182: 411–416.
45.
KayaniMAParryJM. The detection and assessment of the aneugenic potential of selected oestrogens, progestins and androgens using the in vitro cytokinesis blocked micronucleus assay. Mutat Res2008; 651: 40–45.
46.
DornSBBoltHMThevisM. Micronucleus induction in V79 cells by the anabolic doping steroids desoxymethyltestosterone (madol) and 19-norandrostenedione. Toxicol Lett2008; 183: 58–64.
47.
MeirelesJRCOliveiraSVCosta-NetoAO. Genotoxic and cytotoxic effects of testosterone cypionate (deposteron®). Mutat Res2013; 753: 72–75.
48.
RicholdM. The genotoxicity of trenbolone, a synthetic steroid. Arch Toxicol1988; 61: 249–258.
49.
HoldenHEStudwellDMajeskaJB. Oxymetholone: I. Evaluation in a comprehensive battery of genetic toxicology and in vitro transformation assays. Toxicol Pathol1999; 27: 501–506.
50.
AhmadMEShadabGGAzferMA. Effect of oxymetholone on SCE frequency in human lymphocyte chromosomes in vitro. Teratogen Carcin Mut2003; Suppl 1: 267–272.
51.
LiehrJG. Is estradiol a genotoxic mutagenic carcinogen?Endocr Ver2000; 21: 40–54.
52.
HartmannAPlappertURaddatzK. 1994. Does physical activity induce DNA damage?Mutagenesis1994; 9: 269–272.
53.
WierzbaTHOlekRAFedeliD. Lymphocyte DNA damage in rats challenged with a single bout of strenuous exercise. J Physiol Pharmacol2006; 57: 115–131.
54.
PavãoPRGGontijoÁMMCRibeiroDA. Ausência de efeito genotóxico induzido por esteróides anabolizantes em indivíduos fisiculturistas. Rev Bras Educ Fís Esp2007; 21: 5–10.
55.
ReichholdSNeubauerOEhrlichV. No acute and persistent DNA damage after an ironman triathlon. Cancer Epidemio Biomarkers Prev2008; 17: 1913–1919.
56.
KeslerTSandhuRSKrishnamoorthyS. Hepatology: hepatocellular carcinoma in a young man secondary to androgenic anabolic steroid abuse. J Gastroenterol Hepatol2014; 29: 1852.
57.
RobertsJTEssenhighDM. Adenocarcinoma of prostate in 40-year-old body-builder. Lancet1986; 2: 742.
58.
WelderAARobertsonJWMelchertRB. Toxic effects of anabolic-androgenic steroids in primary rat hepatic cell cultures. J Pharmacol Toxicol1995; 33: 187–195.
59.
JasiurkowskiBRajJWisingerD. Cholestatic jaundice and IgA nephropathy induced by OTC muscle building agent superdrol. Am J Gastroenterol2006; 101: 2659–2662.
ElsharkawyAMMcPhersonSMassonS. Cholestasis secondary to anabolic steroid use in young men. BMJ2012; 344: e468.
62.
CatlinDHAhrensBDKucherovaY. Detection of norbolethone, an anabolic steroid never marketed, in athletes’ urine. Rapid Commun Mass Spectrom2002; 16: 1273–1275.
63.
SekeraMHAhrensBDChangI-C. Another designer steroid: discovery, synthesis, and detection of “madol” in urine. Rapid Commun Mass Spectrom2005; 19: 781–784.
64.
LootensLMeulemanPLeroux-RoelsG. Metabolic studies with promagnon, methylclostebol and methasterone in the uPA+/+-SCID chimeric mice. J Steroid Biochem2011; 127: 374–381.
